diabetestalk.net

Lantus Pen Vs Vial Cost

How To Get Insulin At A Cheaper Price

How To Get Insulin At A Cheaper Price

Insulin can be expensive. If you’re one of the 6 million Americans with diabetes relying on this main-stay treatment, you could be paying out-of-pocket costs anywhere from $120 to $400 per month, according to a 2015 New England Journal of Medicine commentary. Drugs such as Lantus (insulin glargine) and Levemir (insulin detemir) have seen significant cost increases, according to a recent trend report by pharmacy benefit manager Express Scripts. One reason for the high prices is the lack of generic options for insulin. So for now, you’re stuck having to search around to find affordable options. Where do you shop for more affordable insulin? For some people though, high drug costs can mean making difficult financial choices. Our national polls show people might cut back on groceries and paying bills to pay for their medications. To minimize your costs, consider these options: Prescription Assistance Programs If you don’t have health insurance or are without drug coverage, look into applying for a patient assistance program (PAP). Through the nonprofit NeedyMeds, you can find some programs that offer free or low-cost insulin as long as you meet the eligibility requirements. Those are usually based on your insurance status, income, and diagnosis. You might also qualify for a diagnosis-specific program that can help you save on syringes, pumps, and other diabetes supplies. Pharmacists are also a great resource and can help you find a PAP that meets your financial needs. Switch Drugs Another way to save is by asking your doctor whether there’s a lower-priced insulin that’s right for you. While “long-acting” is a more popular type of insulin, it's also more expensive, but that doesn’t necessarily mean it works better. “It’s mostly a marketing ploy,” says M Continue reading >>

Insulin Vials Vs. Insulin Cartridges: Further Cost Considerations

Insulin Vials Vs. Insulin Cartridges: Further Cost Considerations

Go to: 1. Introduction Diabetes is difficult to control and treatment involves several approaches which are associated with different costs. In the Royal Medical Services (RMS), after diagnosis of the disease and by excluding the regular visits to the clinics, the core costs incurred by the RMS in diabetes treatment can be confined to the cost of medications dispensed to patients and hospitalization due to diabetes complications. Many patients need insulin in the regimen of diabetes treatment. For outpatients, insulin can be administered by two main approaches: traditional vials and cartridges. In the RMS, both approaches are available; however, it is believed that adopting one of these approaches could be more cost-effective from the RMS perspective. Both types of insulin packages contain 100 IU/ml of biphasic insulin aspart. The vial contains 10 ml (1000 IU), while the cartridge used to refill the pen contains 3 ml (300 IU). Although, it is assumed that both approaches produce the same pharmacological outcomes, the ease of use and patient adherence have been compared widely in the literature (Baser et al., 2010; Bohannon, 1999; Rakel, 2009). The comparison between these approaches strongly favors the use of cartridges due to many reasons, for example, pens provide more accurate dosing, less pain due to smaller needle gauge, increased social acceptability and better quality of life (Bohannon, 1999); moreover, patient adherence was improved by using pens without significant increase in the cost (Baser et al., 2010). A study conducted in Mayo Clinic found that converting patients to insulin pens provided an overall cost savings (Ward and Aton, 2011). Another study, in the USA, found that overall annual health care costs were significantly decreased by starting or convert Continue reading >>

Possibly Switching To Vial And Syringe?

Possibly Switching To Vial And Syringe?

Registration is fast, simple and absolutely free so please,join our community todayto contribute and support the site. This topic is now archived and is closed to further replies. So I was diagnosed with T1 about six weeks ago. I'm on 20 units of Lantus at night and take Humalog with meals. This is recent, since my honeymoon phase only lasted two weeks, so the initial treatment no longer worked. Anyway, I've had very good control of my BG since starting the basal/bolus therapy. I don't really go above 120, but I'm usually around 90. But I'm really careful about carb counting, exercise, the whole thing. Anyway, I'm just saying that I really like being on the Lantus and Humalog. However, I'm a little worried about the cost. I'm using disposable pens for both, so my copay for the five-pen prescription is about 90 each. I'm 20 and newly married, and my husband is still in school. He has a pretty good job, but I don't want to be spending half of what we earn on diabetic supplies. I've been thinking about switching to vial and syringe instead of the pens for cost reasons. I was just wondering about your personal thoughts on vial/syringe versus pens. Is it really all that inconvenient? Because when I was taught both methods in the hospital, it didn't seem that bad. Also, can the opened vials be kept at room temp. like with opened pens? I know that people with vials usually end up wasting a lot. I take 20 units of Lantus and about the same of Humalog a day, so I don't know how much I'd be wasting. I guess I'd just really appreciate any comments you have on the pen versus vial/syringe issue. I don't want something that's going to be terribly inconvenient, but I also don't want to be stressing about whether or not I'll be able to afford my insulin when my current supply starts r Continue reading >>

Patient Satisfaction And Costs Associated With Insulin Administered By Pen Device Or Syringe During Hospitalization

Patient Satisfaction And Costs Associated With Insulin Administered By Pen Device Or Syringe During Hospitalization

Study design. This prospective, randomized, controlled, parallel-group study compared the use of pen devices with conventional vials and syringes for the administration of insulin in hospitalized patients with diabetes mellitus requiring subcutaneous injections. A noninferiority study design was used to evaluate patient satisfaction and cost savings with insulin pens versus vials and syringes. Patients were randomly assigned (1:1) to receive their insulin using pen devices or vials and syringes. The study was conducted in accordance with the Declaration of Helsinki.[ 16 ] The procedures for the study were followed in accordance with the ethical standards of the investigational review board at Creighton University and Alegent Health System. Written informed consent was obtained from all patients prior to any trial-related activities. Patients were recruited from two general medicalsurgical units from July 2005 to May 2006. Two prefilled, disposable insulin pen devices were used: InnoLet and FlexPen (Novo Nordisk). Because the hospital has one preferred formulary manufacturer for insulin analogues, orders from prescribers for comparable insulin analogues were therapeutically substituted with an analogue of the hospital's preferred manufacturer whenever possible. Patients received InnoLet if they were randomized to the insulin pen group and prescribed insulin human regular, isophane insulin human (NPH insulin), or the combination of 70% NPH insulin and 30% regular insulin. Patients received the FlexPen if they were randomized to the insulin pen group and prescribed any rapid-acting insulin (insulin lispro or insulin aspart) or the combination of 70% insulin aspart protamine with 30% insulin aspart or 75% insulin lispro protamine with 25% insulin lispro. NovoFine Autocover Continue reading >>

Is The Insulin Pen Mightier Than The Syringe?

Is The Insulin Pen Mightier Than The Syringe?

Is the Insulin Pen Mightier Than the Syringe? Is the Insulin Pen Mightier Than the Syringe? Nonadherence to antidiabetic therapies represents a major challenge to clinicians treating patients with diabetes. Adherence rates range from 62% to 64% for patients with type 2 diabetes mellitus (T2DM) taking insulin therapy .1 Barriers to adherence include "complicated regimens, fear of injection pain, social embarrassment, lack of confidence about self-injection, perception of injectable therapy as inconvenient, and belief that insulin use is the last resort."2 Additional barriers to adherence are patients' fears about insulin-induced hypoglycemia3 and physicians' delay of initiation of insulin therapy, due to concerns about nonadherence.4 Improving adherence to medication regimens is critical, as nonadherence leads to poorer glycemic control and increased risk of diabetic complications.2 POLL: Which Are Better: Syringes, or Insulin Pens? Vote Now! Moreover, greater medication adherence has been found to be associated not only with improved glycemic control but also with decreased health care utilization.5 Therefore, it is important to examine the most effective means of increasing adherence in patients with T2DM. Insulin pen devices incorporate the insulin and syringe in a single unit and have been found to address some of the barriers to adherence, as compared to conventional vials/syringes.2 Reasons that patients prefer pen devices include that they are easier to use, are more discrete, and elicit less fear in terms of self-injection.2 Additionally, pens may have greater dosing accuracy, compared with vials and syringes.2 Several observational studies have found greater adherence with insulin pens than with vials/syringes.6,7,8,9 Although insulin pens are associated with h Continue reading >>

The Cost Of Insulin

The Cost Of Insulin

The price of insulin has more than tripled in ten years. Not everybody pays full price, but many find the cost of insulin complicates their life. This week, we’ll cover why insulin prices are so high. Next week, we’ll address what to do about it. According to this story on CBS News, people with diabetes are “cutting back [on their insulin doses] or even going without the drug,” putting them at greater risk for complications. Insulin costs have soared from $100–$200 per month a few years ago to $400–$500 a month now. CBS News quotes a college student saying her bill for insulin has risen from $130 to $495 per month. She has given up her insulin pump and gone back to injections because of expense. One of her friends has cut her dose down to 80% of what’s ordered to save money. This has become common practice for many. A doctor in Montana reported that insulin prices greatly complicate people’s care. “I have patients who tell me that they have to make a decision between food and insulin, and their rent and insulin.” Why is this happening? When insulin was discovered the 1920s, the doctors who found it gave it away. It immediately started saving lives for people with Type 1 diabetes. Now insulin has become a $24-billion-a-year market globally and is predicted to pass $48 billion in only five more years. And people around the world who need it can’t afford it. There are several causes for the price spikes, but many of them come down to America’s pretend “free market” approach to health care. We are seeing these problems now with the controversy over one brand of epinephrine injections, whose manufacturer increased their price by 500% and then paid their CEO a nearly $19 million salary. Here are some ways American economics are making insulin unaff Continue reading >>

How To Find A Lantus Coupon

How To Find A Lantus Coupon

It looks like this page may be out of date. Please visit NerdWallet’s health hub for our latest content. Diabetics don’t have much of a choice when it comes to taking their insulin, and the costs can be very high, so a Lantus coupon can be invaluable. Paired with diabetic supplies like syringes and blood glucose testing equipment, diabetes is an expensive disease. But with a little bit of information and some resourcefulness, you may be able to save on your monthly prescriptions. Lantus is a long-acting insulin made by Sanofi-Aventis and prescribed to both Type 1 and Type 2 diabetics. Diabetics are unable to naturally produce or use insulin like most people, so they take injections of synthetic insulin to help regulate their blood sugar. Generic Lantus At this time, there is no generic form of Lantus available. However, that may soon change. The patents protecting Lantus from cheaper generic alternatives expired in February 2015, so less expensive forms of the drug may be coming. When this happens, opting for generic will likely be the best way to save on Lantus, and because of FDA requirements, you don’t have to worry about the generic version being less effective or less safe. Although some people avoid buying generics because they are afraid they won’t work as well as the name brands, those fears are largely unfounded. Lantus coupons from the manufacturer One carton of Lantus can cost close to $400 without insurance, according to GoodRx.com, though Lantus may very well be part of your insurance formulary. Currently, the maker of the drug offers a Lantus Savings Card. According to its website, the card can reduce your prescription cost to no more than $25. However, it also says there is a maximum benefit of $100 off each prescription for the duration of the pr Continue reading >>

Improved Disposable Insulin Pen Devices Provide An Alternative To Vials And Syringes For Insulin Administration

Improved Disposable Insulin Pen Devices Provide An Alternative To Vials And Syringes For Insulin Administration

The prevalence of diabetes has increased so rapidly during the past 30 years that the condition is now a problem of national importance in the United States. It has been estimated that 12.3% of individuals aged 20–79 years in the United States (26.8 million people) have diabetes, and the vast majority of those have type 2 diabetes.1 Diabetes has devastating effects on patient morbidity and mortality that, in turn, place a substantial economic burden on the nation's health care resources. In 2010, an estimated 231,000 deaths among people aged 20–79 years in the United States were attributable to diabetes, and the mean annual health expenditure per person with diabetes was $7,383.1 Morbidity and mortality and the associated costs of treatment in diabetes are primarily due to hyperglycemia; achieving and maintaining optimal glycemic control is important for both patients with type 1 diabetes and those with type 2 diabetes to reduce the risk of developing long-term complications.2,3 Typically, in patients with type 1 diabetes, glycemic control is achieved from the time of diagnosis with insulin, whereas in type 2 diabetes, the addition of insulin to an initial regimen of oral antidiabetes drugs (OADs) is known to confer benefits in terms of reduced risk of long-term complications.4 However, although the importance of maintaining optimal glycemic control in diabetes is well documented, insulin therapy is widely underused in the United States,5 largely because a number of barriers to initiation of and adherence to insulin therapy exist such as fear of injections (including self-injection).6,7 Insulin pen delivery devices such as the SoloSTAR (sanofi-aventis, Paris, France), the FlexPen (Novo Nordisk A/S, Bagsvaerd, Denmark), and the KwikPen (Eli Lilly, Indianapolis, Ind.) Continue reading >>

Is Lantus In A Vial Less Expensive Than A Pen?

Is Lantus In A Vial Less Expensive Than A Pen?

Home Q & A Questions Is lantus in a vial less... Is lantus in a vial less expensive than a pen? It would cost less, but its not cheap. You can go to the lantus web site for assistance. lantus.com Still looking for answers? Try searching for what you seek or ask your own question . What if blood went inside the lantus solostar pen? 21 year old son "thought" he had another lantus pen, he doesn't and it being Saturday night our? The easiest way to lookup drug information, identify pills, check interactions and set up your own personal medication records. Available for Android and iOS devices. Subscribe to receive email notifications whenever new articles are published. Drugs.com provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines and natural products. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment. Data sources include Micromedex (updated Feb 28th, 2018), Cerner Multum (updated Mar 15th, 2018), Wolters Kluwer (updated Mar 1st, 2018) and others. To view content sources and attributions, please refer to our editorial policy . Continue reading >>

How Do I Get Lantus Insulin Less Expensively?

How Do I Get Lantus Insulin Less Expensively?

November 2, 2013-- How do I get Lantus Insulin Less Expensively? DCIN receives this question a few times a week from US caregivers of diabetic cats. I am often amazed by the question because of the “good” insulins for diabetic cats, Lantus can be the least expensive per unit. The problem often lies in knowing how to find the insulin inexpensively. (The hints I give also apply to Levemir, another human insulin often used by diabetic cats.) Your vet gave you a prescription that probably read “U100 Glargine/Lantus 10ml vial.” Lantus is the brand name for the generic insulin Glargine. Lantus is an insulin for humans and is only available from a human pharmacy (although some vets do hold some in stock). The company Sanofi makes Lantus, and no other companies currently make a generic Glargine because Sanofi still has an international patent on the insulin. That may change in 2014, and by then Sanofi may have developed a “second-generation” Lantus that is patent protected. Lantus is a U100 insulin, which describes the concentration of the insulin in the liquid suspension. A 10ml vial is the insulin’s containment device. It is a small glass bottle with a rubber stopper at the end that you pierce with a syringe. At a US retail pharmacy, a 10ml vial of Lantus can cost about $180 to $200. WOWZA! That does seem cause for sticker shock. A 10ml vial of U100 insulin holds 1000 units of insulin. At $200/vial, that is a price of $.20/unit. If your cat gets 2 units of insulin twice a day, that is $.80/day for its insulin (if you could completely use a vial of Lantus insulin). It would cost less each day to give your cat its life-saving medicine that to buy a soda from a vending machine. However, the problem with buying Lantus in a 10ml vial is that, properly handled, Lantus Continue reading >>

Lantus (insulin Glargine) Cost, Dosage, Prescribing Information And Side Effects

Lantus (insulin Glargine) Cost, Dosage, Prescribing Information And Side Effects

Brand Name: Lantus Generic Name: insulin Glargine (rDNA Origin) Injection (vials and SoloStar) Medication Class: Long-Acting Insulin Manufacturer: Sanofi Aventis US FDA Approval Date: April 20, 2000 What is Lantus and its mechanism of action? Lantus (Insulin Glargine) is a long-acting type of insulin used for treating diabetes. Lantus is a biologic drug made by using recombinant DNA (rDNA) technology. Insulin is a hormone produced and released by beta cells in the pancreas. Insulin is released to help the body regulate blood glucose. Insulin release is triggered by an increase in blood glucose from food consumption. Lantus is a basal insulin analogue and it is equivalent to human insulin but it has a slower onset, no pronounced peak, and longer duration of action. Like other types of insulin Lantus regulates the use of glucose by the body. It lowers blood glucose by stimulating glucose uptake by skeletal muscle and adipose tissue, and also reducing glucose production in the liver. Insulin enhances protein production and reduces the breakdown of protein into smaller protein molecules (polypeptides) and breakdown of fats to release fatty acids. What is Lantus used for treating? Lantus is used to lower blood glucose and improve diabetes control in adult and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus. How effective is Lantus? In multiple studies in adults and pediatric patients with type 1 or type 2 diabetes the effect of Lantus given once daily at bedtime on reducing glycated hemoglobin (HbA1C) was measured and compared against NPH once daily and twice daily. In two of the clinical studies, adult patients with type 1 diabetes were given Lantus or NPH insulin for 28 weeks. Regular insulin was administered before each meal. B Continue reading >>

Insulin Pens: Improving Adherence And Reducing Costs

Insulin Pens: Improving Adherence And Reducing Costs

The advantages offered by insulin pens may help improve patient adherence. Currently 8.3% of the United States adult population, or 25.8 million people, have diabetes. Of these cases, more than 90% are cases of type 2 diabetes mellitus (T2DM) and at least 1 million are estimated to be cases of type 1 diabetes mellitus (T1DM). Although a variety of oral medications are available for patients with diabetes, insulins remain an important component of treatment.1,2 Insulins are the standard therapy in patients with T1DM and are ultimately used in patients with T2DM who do not respond adequately to other treatment modalities. Although in some settings insulins may be administered intravenously (eg, with an insulin pump), the vast majority of insulin administrations are subcutaneous injections.1,2 Available Forms and Administration In the United States, 2 types of insulins are available: recombinant human insulins and insulin analogs. Recombinant human insulin is available from 2 manufacturers (Humulin by Eli Lilly and Novolin by Novo Nordisk); each of these is available in a regular form and in a longer-acting neutral protamine hagedorn (NPH) form. Unlike recombinant human insulins, insulin analogs are structurally modified forms of insulin that are designed to either lower blood sugar rapidly or maintain low blood sugar levels over time. These insulin analogs may be classified as rapid-acting and long-acting insulins. Rapid-acting insulins include insulin lispro, insulin aspart, and insulin glulisine, and long-acting insulins include insulin glargine and insulin detemir. Premixed formulations of insulin are also available.1,2 Regardless of the differences between insulin formulations, all conventional types of insulin can be administered subcutaneously. Subcutaneous injectio Continue reading >>

Insulin Pens: Improving Adherence And Reducing Costs

Insulin Pens: Improving Adherence And Reducing Costs

Insulin Pens: Improving Adherence and Reducing Costs The advantages offered by insulin pens may help improve patient adherence. Currently 8.3% of the United States adult population, or 25.8 million people, have diabetes. Of these cases, more than 90% are cases of type 2 diabetes mellitus (T2DM) and at least 1 million are estimated to be cases of type 1 diabetes mellitus (T1DM). Although a variety of oral medications are available for patients with diabetes, insulins remain an important component of treatment.1,2 Insulins are the standard therapy in patients with T1DM and are ultimately used in patients with T2DM who do not respond adequately to other treatment modalities. Although in some settings insulins may be administered intravenously (eg, with an insulin pump), the vast majority of insulin administrations are subcutaneous injections.1,2 In the United States, 2 types of insulins are available: recombinant human insulins and insulin analogs. Recombinant human insulin is available from 2 manufacturers (Humulin by Eli Lilly and Novolin by Novo Nordisk); each of these is available in a regular form and in a longer-acting neutral protamine hagedorn (NPH) form. Unlike recombinant human insulins, insulin analogs are structurally modified forms of insulin that are designed to either lower blood sugar rapidly or maintain low blood sugar levels over time. These insulin analogs may be classified as rapid-acting and long-acting insulins. Rapid-acting insulins include insulin lispro, insulin aspart, and insulin glulisine, and long-acting insulins include insulin glargine and insulin detemir. Premixed formulations of insulin are also available.1,2 Regardless of the differences between insulin formulations, all conventional types of insulin can be administered subcutaneously. Su Continue reading >>

Comparing Insulin Vials To Pens – Comparison Of Charges, Not Healthcare Benefits

Comparing Insulin Vials To Pens – Comparison Of Charges, Not Healthcare Benefits

Type 2 diabetes mellitus (T2DM) is a progressive disease. Insulin resistance is an underlying pathophysiological mechanism in T2DM. However, insulin deficiency also plays a role, especially with disease progression. Insulin therapy forms an important cornerstone for treatment of T2DM1. In their publication ‘The association between use of mealtime insulin pens versus vials and healthcare charges and resource utilization in patients with type 2 diabetes: A retrospective cohort study’2, the authors compare the healthcare charges and utilization of both inpatient and outpatient resources associated with initiating mealtime insulin in the form of a pen as compared to a vial. Several factors need to be considered and discussed while interpreting the results of this study in the clinical context of managing patients with T2DM, especially those on insulin regimen. In addition to the mealtime insulin analogs, mixed insulin preparations were used in the inclusion criteria. The proportion of patients using mixed insulin preparations in the pen vs the vial cohort is not known. With the use of a mixed insulin preparation, patients get part of their basal insulin in addition to the mealtime insulin in the same injection. This results in a decreased number of injections per day, leading to a decreased need for pen needles and syringes, which impacts cost. The outpatient component of the diabetes related charges was $4,659.6 ± $2,299.9 for the pen cohort vs $5,340.3 ± $2,803.3 for the vial cohort; p < 0.0001). The decreased number of injections may also contribute to the decreased charges. Interestingly, the drug charges are lower for the vial cohort as compared to the pen cohort for the outpatient component of the outpatient diabetes related charges ($3,592.6 ± $793.3 vs $2,755 Continue reading >>

Grudge Match: Pens Vs. Syringes

Grudge Match: Pens Vs. Syringes

Taking insulin is a cornerstone of care for millions who have diabetes, and the most common method of insulin delivery in the U.S. is injection via needle and syringe. Roughly 20% of insulin users wear an insulin pump, 15% use insulin pens, and less than 1% use jet injectors. Insulin pumps can be expensive, with the average price hovering around $6,500, not including the disposable supplies that have to be replenished regularly, such as infusion sets, cartridges, and batteries. Although jet injectors may seem like a dream come true for patients who fear needles, they have been known to cause bruising and more pain than injections. The big question is why insulin pens are not more popular in the U.S., whereas in Europe and Japan, they comprise from 66% to 75% of insulin prescriptions. It’s not for lack of patient appreciation: In the November 2011 issue of the Journal of Diabetes Science and Technology, a review of 43 studies that compared patient- reported outcomes for insulin pen devices found that patients preferred pens over vial and syringe for myriad reasons, including ease of use, less pain, and greater perceived social acceptance. Indeed, patients are generally receptive to pen use — if their physicians bring it up. A study published in the March 2008 issue of Diabetes Care found that physician encouragement had a tremendous impact on pen use: Patients whose physicians discussed insulin pens were 100 times more likely to use an insulin pen than those whose physicians did not discuss pen use or who discouraged pen use. One reason pens have not caught on here may be payer reimbursement, says Maria J. Redondo, MD, PhD, MPH, assistant professor of pediatrics at Baylor College of Medicine in Houston and co-author of the 43-study review. “Pens are more expensive Continue reading >>

More in diabetes